Attention is focusing on whether Celltrion, which has secured domestic copyrights for ARB-based hypertension treatment Edarbi (Azilsartan Medoxomil), will develop a combination that combines Edarbi and Amlodipine.

Attention is focusing on whether Celltrion will also stand out in the hypertension treatment market, which is the domain of traditional pharmaceutical companies.

The Ministry of Food and Drug Safety approved the plan which Celltrion applied to verify the effectiveness and safety of Azilsartan Medoxomil and Amlodipine Besylate for eight weeks on the 17th.

This test is a multicenter, randomized, double-blinded test to compare the effectiveness and safety of 8-week c